18 April 2017

FDA Authorisation to Proceed RPL554 Investigation

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. 

Read more

18 April 2017

FDA Authorisation to Proceed RPL554 Investigation

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. 

Read more

12 April 2017

Result of AGM

 

Read more

5 April 2017

[ENCRYPTED]

[ENCRYPTED]

Read more

4 April 2017

1st Patient Dosed in Ph2a Trial for RPL554 in CF

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.

Read more

4 April 2017

Files Statement for Proposed Global Offering

RNS Number : 4464B Verona Pharma PLC 04 April 2017

Read more

4 April 2017

Verona Pharma Doses First Patient in Phase 2a Clinical Trial Evaluating RPL554 for Cystic Fibrosis

Read more

4 April 2017

Verona Pharma Files Registration Statement for Proposed Global Offering

Read more

3 April 2017

Board Change

FOR RNS RELEASE:

Read more

31 March 2017

Appointment of Commercial Director and dry powder formulation development

Read more

Innovative Therapies for Respiratory Care

See the 2017 Verona Pharma corporate video 2017

Runtime: 04:05

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us